Immunohistochemical analysis of NAD(P)Hquinone oxidoreductase and NADPh cytochrome P450 reductase in human superficial bladder tumours

Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy

Saurajyoti Basu, John E. Brown, G. Michael Flannigan, Jason H. Gill, Paul M. Loadman, Sandie W. Martin, Brian Naylor, Andrew J. Scally, Jill M. Seargent, Tariq Shah, Rajiv Puri, Roger M. Phillips

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A central theme within the concept of enzyme-directed bioreductive drug development is the potential to predict tumour response based on the profiling of enzymes involved in the bioreductive activation process. Mitomycin C (MMC) is the prototypical bioreductive drug that is reduced to active intermediates by several reductases including NAD(P)H:quinone oxidoreductase (NQO1) and NADPH cytochrome P450 reductase (P450R). The purpose of our study was to determine whether NQO1 and P450R protein expression in a panel of low-grade, human superficial bladder tumours correlates with clinical response to MMC. A retrospective clinical study was conducted in which the response to MMC of 92 bladder cancer patients was compared to the immunohistochemical expression of NQO1 and P450R protein in archived paraffin-embedded bladder tumour specimens. A broad spectrum of NQO1 protein levels exists in bladder tumours between individual patients, ranging from intense to no immunohistochemical staining. In contrast, levels of P450R were similar with most tumours having moderate to high levels. All patients were chemotherapy naïve prior to receiving MMC and clinical response was defined as the time to first recurrence. A poor correlation exists between clinical response and NQO1, P450R or the expression patterns of various combinations of the 2 proteins. The results of our study demonstrate that the clinical response of superficial bladder cancers to MMC cannot be predicted on the basis of NQO1 and/or P450R protein expression and suggest that other factors (other reductases or post DNA damage events) have a significant bearing on tumour response.

Original languageEnglish
Pages (from-to)703-709
Number of pages7
JournalInternational Journal of Cancer
Volume109
Issue number5
Early online date22 Jan 2004
DOIs
Publication statusPublished - 1 May 2004
Externally publishedYes

Fingerprint

NADPH-Ferrihemoprotein Reductase
Mitomycin
Urinary Bladder Neoplasms
NAD
Oxidoreductases
Neoplasms
Therapeutics
Proteins
Enzymes
Pharmaceutical Preparations
Paraffin
DNA Damage
Retrospective Studies
Staining and Labeling
Recurrence
Drug Therapy

Cite this

Basu, Saurajyoti ; Brown, John E. ; Flannigan, G. Michael ; Gill, Jason H. ; Loadman, Paul M. ; Martin, Sandie W. ; Naylor, Brian ; Scally, Andrew J. ; Seargent, Jill M. ; Shah, Tariq ; Puri, Rajiv ; Phillips, Roger M. / Immunohistochemical analysis of NAD(P)Hquinone oxidoreductase and NADPh cytochrome P450 reductase in human superficial bladder tumours : Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. In: International Journal of Cancer. 2004 ; Vol. 109, No. 5. pp. 703-709.
@article{f059f63b39b6474a9720cc67552e8257,
title = "Immunohistochemical analysis of NAD(P)Hquinone oxidoreductase and NADPh cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy",
abstract = "A central theme within the concept of enzyme-directed bioreductive drug development is the potential to predict tumour response based on the profiling of enzymes involved in the bioreductive activation process. Mitomycin C (MMC) is the prototypical bioreductive drug that is reduced to active intermediates by several reductases including NAD(P)H:quinone oxidoreductase (NQO1) and NADPH cytochrome P450 reductase (P450R). The purpose of our study was to determine whether NQO1 and P450R protein expression in a panel of low-grade, human superficial bladder tumours correlates with clinical response to MMC. A retrospective clinical study was conducted in which the response to MMC of 92 bladder cancer patients was compared to the immunohistochemical expression of NQO1 and P450R protein in archived paraffin-embedded bladder tumour specimens. A broad spectrum of NQO1 protein levels exists in bladder tumours between individual patients, ranging from intense to no immunohistochemical staining. In contrast, levels of P450R were similar with most tumours having moderate to high levels. All patients were chemotherapy na{\"i}ve prior to receiving MMC and clinical response was defined as the time to first recurrence. A poor correlation exists between clinical response and NQO1, P450R or the expression patterns of various combinations of the 2 proteins. The results of our study demonstrate that the clinical response of superficial bladder cancers to MMC cannot be predicted on the basis of NQO1 and/or P450R protein expression and suggest that other factors (other reductases or post DNA damage events) have a significant bearing on tumour response.",
keywords = "Bladder cancer, Cytochrome P450 reductase, Mitomycin C, NQO1",
author = "Saurajyoti Basu and Brown, {John E.} and Flannigan, {G. Michael} and Gill, {Jason H.} and Loadman, {Paul M.} and Martin, {Sandie W.} and Brian Naylor and Scally, {Andrew J.} and Seargent, {Jill M.} and Tariq Shah and Rajiv Puri and Phillips, {Roger M.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1002/ijc.20005",
language = "English",
volume = "109",
pages = "703--709",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

Immunohistochemical analysis of NAD(P)Hquinone oxidoreductase and NADPh cytochrome P450 reductase in human superficial bladder tumours : Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. / Basu, Saurajyoti; Brown, John E.; Flannigan, G. Michael; Gill, Jason H.; Loadman, Paul M.; Martin, Sandie W.; Naylor, Brian; Scally, Andrew J.; Seargent, Jill M.; Shah, Tariq; Puri, Rajiv; Phillips, Roger M.

In: International Journal of Cancer, Vol. 109, No. 5, 01.05.2004, p. 703-709.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunohistochemical analysis of NAD(P)Hquinone oxidoreductase and NADPh cytochrome P450 reductase in human superficial bladder tumours

T2 - Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy

AU - Basu, Saurajyoti

AU - Brown, John E.

AU - Flannigan, G. Michael

AU - Gill, Jason H.

AU - Loadman, Paul M.

AU - Martin, Sandie W.

AU - Naylor, Brian

AU - Scally, Andrew J.

AU - Seargent, Jill M.

AU - Shah, Tariq

AU - Puri, Rajiv

AU - Phillips, Roger M.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - A central theme within the concept of enzyme-directed bioreductive drug development is the potential to predict tumour response based on the profiling of enzymes involved in the bioreductive activation process. Mitomycin C (MMC) is the prototypical bioreductive drug that is reduced to active intermediates by several reductases including NAD(P)H:quinone oxidoreductase (NQO1) and NADPH cytochrome P450 reductase (P450R). The purpose of our study was to determine whether NQO1 and P450R protein expression in a panel of low-grade, human superficial bladder tumours correlates with clinical response to MMC. A retrospective clinical study was conducted in which the response to MMC of 92 bladder cancer patients was compared to the immunohistochemical expression of NQO1 and P450R protein in archived paraffin-embedded bladder tumour specimens. A broad spectrum of NQO1 protein levels exists in bladder tumours between individual patients, ranging from intense to no immunohistochemical staining. In contrast, levels of P450R were similar with most tumours having moderate to high levels. All patients were chemotherapy naïve prior to receiving MMC and clinical response was defined as the time to first recurrence. A poor correlation exists between clinical response and NQO1, P450R or the expression patterns of various combinations of the 2 proteins. The results of our study demonstrate that the clinical response of superficial bladder cancers to MMC cannot be predicted on the basis of NQO1 and/or P450R protein expression and suggest that other factors (other reductases or post DNA damage events) have a significant bearing on tumour response.

AB - A central theme within the concept of enzyme-directed bioreductive drug development is the potential to predict tumour response based on the profiling of enzymes involved in the bioreductive activation process. Mitomycin C (MMC) is the prototypical bioreductive drug that is reduced to active intermediates by several reductases including NAD(P)H:quinone oxidoreductase (NQO1) and NADPH cytochrome P450 reductase (P450R). The purpose of our study was to determine whether NQO1 and P450R protein expression in a panel of low-grade, human superficial bladder tumours correlates with clinical response to MMC. A retrospective clinical study was conducted in which the response to MMC of 92 bladder cancer patients was compared to the immunohistochemical expression of NQO1 and P450R protein in archived paraffin-embedded bladder tumour specimens. A broad spectrum of NQO1 protein levels exists in bladder tumours between individual patients, ranging from intense to no immunohistochemical staining. In contrast, levels of P450R were similar with most tumours having moderate to high levels. All patients were chemotherapy naïve prior to receiving MMC and clinical response was defined as the time to first recurrence. A poor correlation exists between clinical response and NQO1, P450R or the expression patterns of various combinations of the 2 proteins. The results of our study demonstrate that the clinical response of superficial bladder cancers to MMC cannot be predicted on the basis of NQO1 and/or P450R protein expression and suggest that other factors (other reductases or post DNA damage events) have a significant bearing on tumour response.

KW - Bladder cancer

KW - Cytochrome P450 reductase

KW - Mitomycin C

KW - NQO1

UR - http://www.scopus.com/inward/record.url?scp=12144287215&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0215

U2 - 10.1002/ijc.20005

DO - 10.1002/ijc.20005

M3 - Article

VL - 109

SP - 703

EP - 709

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -